Variation for Colorectal Treatment

Researchers have found childhood cancer survivors are at risk of experiencing onset of aging-related disease 17.7 years sooner than the general population.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease across leukemia subtypes.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes.

The FDA has approved Stoboclo and Osenvelt to address skeletal issues faced by patients with cancer.